Deborah Hurst

2.3k total citations
32 papers, 1.8k citations indexed

About

Deborah Hurst is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Deborah Hurst has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 14 papers in Genetics and 8 papers in Oncology. Recurrent topics in Deborah Hurst's work include Hemophilia Treatment and Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Deborah Hurst is often cited by papers focused on Hemophilia Treatment and Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Deborah Hurst collaborates with scholars based in United States, Germany and United Kingdom. Deborah Hurst's co-authors include Klara Kleman, Bertram H. Lubin, Elliott Vichinsky, Ann N. Earles, Khang Hoang, Sacha Satram‐Hoang, Bruno C. Medeiros, Carolina Reyes, Jeanne M. Lusher and Richard Prescott and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Deborah Hurst

32 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Hurst United States 17 1.0k 788 373 330 314 32 1.8k
N Philippe France 18 456 0.4× 266 0.3× 255 0.7× 235 0.7× 220 0.7× 59 1.4k
Richard Champlin United States 19 1.1k 1.0× 191 0.2× 332 0.9× 118 0.4× 638 2.0× 52 1.7k
M. Peetermans Belgium 23 1.4k 1.4× 310 0.4× 410 1.1× 99 0.3× 384 1.2× 72 2.2k
G. Solbu Netherlands 21 1.3k 1.3× 382 0.5× 613 1.6× 349 1.1× 707 2.3× 51 2.1k
Robert Delage Canada 18 400 0.4× 305 0.4× 141 0.4× 100 0.3× 178 0.6× 58 957
Paul Cannell Australia 18 519 0.5× 251 0.3× 229 0.6× 102 0.3× 373 1.2× 55 1.1k
Dany Habr United States 27 2.3k 2.2× 2.5k 3.2× 407 1.1× 429 1.3× 163 0.5× 86 2.9k
Muneer H. Abidi United States 22 1.5k 1.4× 321 0.4× 977 2.6× 167 0.5× 1.5k 4.8× 92 2.7k
Jonathan Kell United Kingdom 20 1.9k 1.8× 392 0.5× 1.1k 3.1× 79 0.2× 574 1.8× 57 2.5k
Stephen Schey United Kingdom 20 1.1k 1.1× 218 0.3× 677 1.8× 110 0.3× 894 2.8× 71 1.8k

Countries citing papers authored by Deborah Hurst

Since Specialization
Citations

This map shows the geographic impact of Deborah Hurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Hurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Hurst more than expected).

Fields of papers citing papers by Deborah Hurst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Hurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Hurst. The network helps show where Deborah Hurst may publish in the future.

Co-authorship network of co-authors of Deborah Hurst

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Hurst. A scholar is included among the top collaborators of Deborah Hurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Hurst. Deborah Hurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kipps, Thomas J., Herbert Eradat, Sebastian Grosicki, et al.. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leukemia & lymphoma. 56(10). 2826–2833. 151 indexed citations
2.
Medeiros, Bruno C., et al.. (2015). Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Annals of Hematology. 94(7). 1127–1138. 189 indexed citations
3.
Dakhil, Shaker R., Róbert Hermann, Marshall T. Schreeder, et al.. (2014). Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leukemia & lymphoma. 55(10). 2335–2340. 19 indexed citations
4.
5.
6.
Khan, Khuda Dad, Christos Emmanouilides, Don M. Benson, et al.. (2006). A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. Clinical Cancer Research. 12(23). 7046–7053. 71 indexed citations
7.
Lusher, Jeanne M., C F Abildgaard, Steven Arkin, et al.. (2004). Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. Journal of Thrombosis and Haemostasis. 2(4). 574–583. 61 indexed citations
8.
Gluck, William Larry, Deborah Hurst, Alan R. Yuen, et al.. (2004). Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma. Clinical Cancer Research. 10(7). 2253–2264. 127 indexed citations
9.
10.
Powell, Jerry S., Mark Bush, Ewen M. Harrison, et al.. (2000). Safety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A. Haemophilia. 6(3). 140–149. 15 indexed citations
11.
Singer, Sylvia T., Deborah Hurst, & Joseph E. Addiego. (1997). Bleeding Disorders in Noonan Syndrome: Three Case Reports and Review of the Literature. ˜The œAmerican journal of pediatric hematology/oncology. 19(2). 130–134. 22 indexed citations
12.
Hurst, Deborah & Judith Grant. (1996). Fundamental Feminism: Contesting the Core Concepts of Feminist Theory. The Canadian Journal of Sociology. 21(1). 110–110. 11 indexed citations
13.
Hurst, Deborah. (1995). Clinical development of recombinant factor VIII (rFVIII, Kogenate). Haemophilia. 1(S2). 26–28. 1 indexed citations
14.
Scandella, Dorothea, Craig M. Kessler, Deborah Hurst, et al.. (1995). Epitope specificity and functional characterization of factor VIII inhibitors. Advances in experimental medicine and biology. 386. 47–63. 20 indexed citations
15.
Vichinsky, Elliott, et al.. (1992). Differentiation of homozygous hemoglobin E from compound heterozygous hemoglobin E-β0-thalassemia by hemoglobin E mutation analysis. The Journal of Pediatrics. 120(5). 775–779. 10 indexed citations
16.
Williams, Roger A., et al.. (1989). Transfusion of infants with activation of erythrocyte T antigen. The Journal of Pediatrics. 115(6). 949–953. 38 indexed citations
17.
Burr, M L, Kirsten Phillips, & Deborah Hurst. (1985). Lung function in the elderly.. Thorax. 40(1). 54–59. 48 indexed citations
18.
Katz, Richard S., Deborah Hurst, Danny Chiu, et al.. (1985). GROWTH RETARDATION IN SICKLE-CELL DISEASE TREATED BY NUTRITIONAL SUPPORT. The Lancet. 325(8434). 903–906. 73 indexed citations
19.
Vichinsky, Elliott, Deborah Hurst, Danny Chiu, et al.. (1984). NUTRITION IN SICKLE CELL ANEMIA (HB SS). Pediatric Research. 18. 251A–251A. 6 indexed citations
20.
Hurst, Deborah, et al.. (1983). Anemia and hemoglobinopathies in Southeast Asian refugee children. The Journal of Pediatrics. 102(5). 692–697. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N Philippe Breakdown of academic impact, for papers by Richard Champlin Breakdown of academic impact, for papers by M. Peetermans Breakdown of academic impact, for papers by G. Solbu Breakdown of academic impact, for papers by Robert Delage Breakdown of academic impact, for papers by Paul Cannell Breakdown of academic impact, for papers by Dany Habr Breakdown of academic impact, for papers by Muneer H. Abidi Breakdown of academic impact, for papers by Jonathan Kell Breakdown of academic impact, for papers by Stephen Schey
Rankless by CCL
2026